Autoimmune biotech Kiniksa prices upsized $152M IPO as Scholar Rock bags $75M for preclinical SMA drug
Two biotechs that have been on parallel IPO tracks are blasting off with sizable support for their Nasdaq debuts.
Kiniksa got the bulkier raise among the two, reaping $152 million at $18 a share — up from the $126 million it was looking for — by offering 8.44 million shares, or 21% more than originally planned. Scholar Rock, meanwhile, got what it asked for, pricing its $75 million IPO at the midpoint of $14.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.